Analyst Updates: Insights on Krystal Biotech and More Stocks

Author: Dylan Bailey Updated: 03-05-2025 12:43 PM

Recent Analyst Ratings and Price Targets

The realm of stock analysis is ever-evolving, and recent updates from top analysts reflect significant shifts in their outlook on various stocks. This article delves into the latest coverage and expectations set by industry experts, particularly focusing on Krystal Biotech, Inc. (NASDAQ: KRYS) which has gained notable attention among investors.

Krystal Biotech: A Promising Outlook

Jefferies analyst Roger Song has initiated coverage on Krystal Biotech, Inc. with a bullish Buy rating and has set an ambitious price target of $245. This figure presents a significant upside compared to the recent closing price of approximately $175.22, indicating strong expectations for the company’s performance in the near term.

Marker Therapeutics: Analyst Expectations

In a related update, Canaccord Genuity analyst John Newman has started coverage on Marker Therapeutics, Inc. (NASDAQ: MRKR) with a Buy rating. The suggested price target stands at $8, reflecting optimism about its future trajectory. Marker Therapeutics shares have been trading around $1.38, showcasing potential growth in the coming periods.

Insights on Additional Stocks

Alongside Krystal Biotech and Marker Therapeutics, several other stocks are receiving attention from analysts. For instance, Barclays’ Thomas O’Malley has provided coverage on Sandisk Corporation (NASDAQ: SNDK), assigning an Equal-Weight rating with a price target of $50. Sandisk recently closed at $48.69, indicating a moderately stable outlook within the tech sector.

Fluence Energy and Abeona Therapeutics

Furthermore, Mizuho analyst Maheep Mandloi has initiated coverage on Fluence Energy, Inc. (NASDAQ: FLNC). With an Outperform rating, the price target is set at $8, while Fluence shares were priced at $5.21 recently. This illustrates a positive sentiment towards the company's renewable energy solutions.

Lastly, Oppenheimer’s Francois Brisebois has initiated coverage on Abeona Therapeutics Inc (NASDAQ: ABEO) with an Outperform stance, setting a price target of $16. Abeona shares, priced at $5.07, exhibit a significant potential upside as indicated by the analyst's forecast.

Understanding the Importance of Analyst Coverage

These ratings and price targets play a crucial role in navigating the investment landscape. By providing fresh insights into stock performance, analysts assist investors in making informed decisions, aligning their portfolios with market trends and company forecasts.

Frequently Asked Questions

What is the current stock price of Krystal Biotech?

The most recent closing price of Krystal Biotech is approximately $175.22, with a new price target of $245 set by analysts.

Who is the analyst covering Marker Therapeutics?

Canaccord Genuity analyst John Newman has initiated coverage on Marker Therapeutics, providing a Buy rating and a price target of $8.

What is the significance of analyst ratings?

Analyst ratings provide insights into market expectations and can significantly influence investor decisions and stock prices.

Which companies received new analyst ratings recently?

Recent updates include Krystal Biotech, Marker Therapeutics, Sandisk Corporation, Fluence Energy, and Abeona Therapeutics.

How can I track these stocks and their performance?

Investors can track stock performance through financial news websites and stock market platforms that provide updates on analyst ratings and price revisions.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.